Abstract
Advances in cell and molecular biology have led to a greater cognizance of the therapeutic value of peptides and proteins. Recombinant DNA technology has enabled high level expression of these biological response modifiers and biotechnology has permitted production for clinical use (Baum, 1987). Many peptide and protein drugs are now commercially available. It is abundantly clear that novel peptide and protein drugs having unique pharmacological properties will be used clinically in the coming decades. These will include a vast range of molecules with markedly different properties and actions. Size alone will vary enormously from some metabolism-modulating peptides such as luteinising hormone-releasing hormone (LHRH) a decapeptide of molecular weight 1182 to cardiovascular-active peptides such as tissue plasminogen activator (tPA), 567 amino acids of molecular weight 59,050 (Banga and Chien, 1988).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Aggarawal, B.B., Eessalu, T.E. and Hass, P.E. (1985), Characterisation of receptors for human tumour necrosis factor and their regulation by γ-interferon. Nature, 318:665–667.
Banga, A.K. and Chien, Y.W. (1988), Systemic delivery of therapeutic peptides and proteins. International Journal of Pharmaceutics, 48:15–20.
Baum, R.M. (1987), Biotech industry moving pharmaceutical productions to markets. Chemical Engineering News, 65:11–32.
Cho, Y.W. and Flynn, M. (1989), Oral delivery of insulin. Lancet, 8678/8679:1518–1519.
Clark, R.G., Jansson, J-O., Isaksson, O. and Robinson, I.C.A.F. (1985), Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats. Journal of Endocrinology, 104:53–61.
Collen, D., Stassen, J-M. and Larsen, G. (1988), Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood, 71:216–219.
Damge, C., Michel. C. Aprahamian, M. and Couvreur, P. (1988), New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes, 37:246–251.
Davis, B.K. (1972), Control of diabetes with polyacrylamide implants containing insulin. Experimentia, 28:348.
de Nijs, H., Bouwman, T.R.M. and Eenink, M.J.D. (1988), Controlled peptide delivery using biodegradable microcapsule formulations. Pharmaceutisch. Weekblad Scientific Edition. 10:49.
Eppstein, D.A. and Longenecker, J.P. (1988), Alternative delivery systems for peptides and proteins as drugs. CRC Critical Reviews in Therapeutic Drug Carrier Systems, 5:99–139.
Fujii, S., Yokoyama, T., Ikegawa, K., Sato, F. and Yokoo. N. (1985). Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. Journal of Pharmaceutical Pharmacology, 37:545–549.
Galloway, J.A. and Root, M.A. (1972), New forms of insulin. Diabetes, 21:637–648.
Humphrey, M.J. (1986), Oral delivery of peptide drugs. In, “Delivery Systems for Peptide Drugs”. Eds, S.S. Davis, L. Illum and E. Tomlinson, NATO ASI Series, Plenum Publication Corporation, New York, pp 139–152.
Hutchinson, F.G. and Furr. B.J.A. (1987), Biodegradable carriers for the sustained release of polypeptides. Tibtech, 5:102–106.
Kararli, T.T. (1989), Gastrointestinal absorption of druges. CRC Critical Reviews in Therapeutic Drug Carrier Systems, 6:39–86
Kleinman, R.E. and Walker, W.A. (1989), The development of barrier function of the gastrointestinal tract. Acta Paediatrics Scandinavia Supplement, 351:34–37.
Langer, R. and Folkman, J. (1976). Polymers for the sustained release of proteins and other macromolecules. Nature, 263:797–800.
Matsumura, M. and Saito, S. (1989). Effect of bile salts on the plasma concentration of immunoreactive vasoactive intestinal polypeptide in man. Endocrinology Japan, 36:1521.
Muranishi, S. (1985), Modification of intestinal absorption of drugs by lipoidal adjuvants. Pharmaceutical Research, 2:108–118.
O’Mullane, J.E., Artursson, P. and Tomlinson, E. (1987), Biopharmaceutics of micro-particulate drug carriers. Annals of the New York Academy of Sciences, Biological Approaches to Controlled Delivery of Drugs, 507:120–140.
Overgaard, K., Riis, B.J., Christiansen, C. and Hansen, M.A. (1989), Effect of salcatonin given intranasally on early postmenopausal bone loss. British Medical Journal, 299:477–479.
Peters, G.E., Hutchinson, L.E.F., Hyde,R., McMartin, C. and Metcalfe, S.B. (1987), Effects of sodium 5-methoxysalicylate on macromolecule absorption and mucosal morphology in a vascularly perfused rat gut preparation in vivo. Journal of Pharmaceutical Science, 76:857–861.
Ritschel, W.A. (1989), Biopharmaceutic and pharmacokinetic aspects in the design of controlled release peroral drug delivery systems. Drug Development and Industrial Pharmacy, 15:1073–1103.
Saffran, M., Kumer, G.S., Savariar, C., Burnham, J.C., Williams, F. and Neckers, D.C. (1986), A new approach to the oral administration of insulin and other peptide drugs. Science, 233:1081–1084.
Shichira, M., Kawamori, R., Goriya, Y., Kikuchi, M., Hakui, N. and Abe, H. (1978), Increased intestinal absorption of insulin in a micellar solution: water-in-oil-in-water insulin micelles. Acta Diabetologia Letters, 15:175–183.
Steiner, S.S. and Rosen, R. (1988), International Patent Application no WO 88/01213.
Tomlinson, E. (1989), Considerations in the physiological delivery of therapeutic proteins. In, “Novel Drug Delivery and its Therapeutic Application”. Eds, L.F. Prescott and W.S. Nimmo, John Wiley and Sons Ltd, Chichester, pp 245–262.
van Hoogdalem. E.J., de Boer, A.G. and Breimer, D.D. (1989) Intestinal drug absorption enhancement: an overview. Pharmaceutical Therapeutics, 44:407–443.
Weiner, A.L. (1989), Liposomes as carriers for polypeptides. Advanced Drug Delivery Reviews,3:307–342.
Yoshikawa, H., Takada, K., Satoh, Y., Naruse, N. and Muranishi, S. (1986), Development of interferon suppositories. I. Enhanced rectal absorption of human fibroblast interferon by fusogenic lipid via lymphotropic delivery in rats. Pharmaceutical Research, 3:116.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Mackay, M. (1990). Delivery of Therapeutic Peptides and Proteins. In: Crommelin, D.J.A., Schellekens, H. (eds) From Clone to Clinic. Developments in Biotherapy, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-3780-5_42
Download citation
DOI: https://doi.org/10.1007/978-94-011-3780-5_42
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5683-0
Online ISBN: 978-94-011-3780-5
eBook Packages: Springer Book Archive